Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Targeting mutant p53 in human tumors.

Lehmann BD, Pietenpol JA.

J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412. Epub 2012 Sep 10. Review. No abstract available.

PMID:
22965952
2.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
3.

Mutant p53 as a target for cancer treatment.

Duffy MJ, Synnott NC, Crown J.

Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul 28. Review.

PMID:
28756138
4.

Pharmacological rescue of p53 in cancer cells: the soloist meets the PRIMA donna.

Hafsi H, Hainaut P.

Cell Cycle. 2011 Mar 15;10(6):875-6. Epub 2011 Mar 15. No abstract available.

PMID:
21358263
5.

p53-targeted cancer pharmacotherapy: move towards small molecule compounds.

Kim SH, Dass CR.

J Pharm Pharmacol. 2011 May;63(5):603-10. doi: 10.1111/j.2042-7158.2010.01248.x. Epub 2011 Mar 31. Review.

PMID:
21492161
6.

Improving cancer therapy through p53 management.

Haupt S, Haupt Y.

Cell Cycle. 2004 Jul;3(7):912-6. Epub 2004 Jul 2. Review.

PMID:
15254405
7.

Activation of p53 by specific agents in potential cancer therapy.

Ho JW, Song JZ, Leung YK.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):131-5. Review.

PMID:
15777220
8.

Personalized-medicine trials on the rise.

Benowitz S.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24. No abstract available.

PMID:
23008496
9.

[Exquisite sensitivity of TP53 mutant breast cancers to dose-dense chemotherapy].

Lehmann-Che J, Turpin E, Bertheau P, Espié M, de Thé H.

Med Sci (Paris). 2007 Nov;23(11):1021-3. French. No abstract available.

10.

Reactivation of mutant p53: a new strategy for cancer therapy.

Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG.

Semin Cancer Biol. 1998;8(5):369-78. Review.

PMID:
10101802
11.

Unleash the wild type: restoration of p53 suppressive activity in skin cancer.

Madar S, Stambolsky P, Rotter V.

Cell Cycle. 2011 Mar 1;10(5):736-7. Epub 2011 Mar 1. No abstract available.

PMID:
21311232
12.

The genetics of the p53 pathway, apoptosis and cancer therapy.

Vazquez A, Bond EE, Levine AJ, Bond GL.

Nat Rev Drug Discov. 2008 Dec;7(12):979-87. doi: 10.1038/nrd2656. Review.

PMID:
19043449
13.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

14.

Current and future medical therapy, and the molecular features of adrenocortical cancer.

Hubalewska-Dydejczyk A, Jabrocka-Hybel A, Pach D, Gilis-Januszewska A, Sokołowski G.

Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):132-45. Review.

PMID:
21854357
15.

[Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology].

Merlio JP.

Ann Pathol. 2011 Nov;31(5 Suppl):S40-2. doi: 10.1016/j.annpat.2011.08.020. Epub 2011 Oct 11. French. No abstract available.

PMID:
22054456
16.

Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

Selivanova G, Wiman KG.

Oncogene. 2007 Apr 2;26(15):2243-54. Review.

PMID:
17401433
17.

Biology-driven phase II trials: what is the optimal model for molecular selection?

Andre F, Delaloge S, Soria JC.

J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22. No abstract available.

PMID:
21343554
18.

Improving pharmacological rescue of p53 function: RITA targets mutant p53.

Girardini JE, Del Sal G.

Cell Cycle. 2010 Jun 1;9(11):2062. Epub 2010 Jun 1. No abstract available.

PMID:
20559030
19.
20.

P53: an old dog begins to learn new tricks.

Malkin D.

Drug Discov Today. 2003 Jul 1;8(13):574-5. No abstract available.

PMID:
12850330

Supplemental Content

Support Center